Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxytocin effects on neural activation in schizophrenia
NCT02568709Phase 1Completed
- Sponsor
- University of California, San Francisco
- Start
- Feb 2012
- Primary completion
- Dec 2016
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of oxytocin nasal spray in schizophrenia (2 arms), sponsored by University of California, San Francisco. Primary endpoint: Change in MEG neural activation patterns at 1 week. Started Feb 2012; status: completed.
02
Drugs
oxytocin nasal spray
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02568709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02568709.